Intellia Therapeutics Raises $100 Million in a Public Offering

Rare Daily Staff

Fresh on the heels of expanding its collaboration with Regeneron Pharmaceuticals expanding their existing collaboration to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B, Intellia Therapeutics raised $100 million in a public offering.

The biotech sold 5.5 million shares of its common stock at $18.25 per share and granted the underwriters a 30-day option to purchase up to an additional 821,917 shares.

Intellia Therapeutics develops proprietary, curative therapeutics using the CRISPR/Cas9 system with a pipeline that includes in vivo and ex vivo programs to develop product candidates addressing a broad range of genetic and oncological diseases. Besides its collaboration with Regeneron, Intellia has partnered with Novartis in sickle cell disease and oncology. It also has several unpartnered preclinical candidates in its pipeline.